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ABSTRAK
Kanker prostat adalah keganasan di bidang urologi yang paling sering bermetastasis ke tulang sampai 70% 
kasus. Penyulitnya berupa nyeri hebat, fraktur patologis, sindroma kompresi tulang belakang dan hiperkalsemia. 
Insidensi penyulit ini sekitar 46,1%, yang mengakibatkan peningkatan biaya perawatan dan memperburuk 
prognosis pasien.
Androgen deprivation therapy merupakan terapi baku kanker prostat yang telah bermetastasis. Terapi ini 
sendiri menyebabkan osteopenia atau osteoporosis.
Bifosfonat merupakan obat yang paling banyak dipakai saat ini untuk terapi metastasis tulang. Bifosfonat 
menghambat secara langsung aktifitas osteoclast dan secara tidak langsung melalui osteoblast. Denosumab 
merupakan opsi terapi terkini pada kasus metastasis tulang dengan efikasi yang lebih baik dari asam zoledronat. 
Efek samping denosumab sebanding dengan penggunaan bifosfonat.
Kata kunci: kanker prostat, metastasis tulang, bone loss, terapi.
ABSTRACT
Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The 
incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression 
syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient’s prognosis.
Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia 
or osteoporosis.
Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. 
Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is 
better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are 
comparable.
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INTRODUCTION
Prostate cancer is diagnosed in more than 670 
000 men yearly worldwide.1.2 In the United States, 
an estimated 217,730 new casesin 2010, it is 28% 
of all cancer incidences in men.3 In developed 
countries, the majority of prostate cancers are 
found at an early stage as much as 75%, even in 
the U.S. by 95%. Indonesian Society of Urologic 
Oncology (ISUO) data shows during the period 
2006-2010 there wasstage 4; 490 patients 
(50.5%) of 971 prostate cancer patients.4 In Hasan 
Sadikin Hospital in the period 2004-2010 found 
57% of cases are still organ confined and locally 
advanced, the remaining 43% of 320 cases were 
advanced stage cases. Fifteen percent of patients 
suffering from pathological fractures.
Prostate cancer is a malignancy in urology 
is the largest cause of bone metastases 65-
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75% compared to the other malignancy.5,6 
Complications of bone metastases=Skeletal 
Related Events (SRE) causes immobilization 
of the patient due to severe pain, pathological 
fractures, spinal compression syndrome and 
hypercalcemia.5 SRE incidence about 46% in 
prostate cancer patientswho affects the cost of 
patient care and worsening prognosis.
Androgen deprivation therapy (ADT) as the 
standard therapy of advanced prostate cancer 
caused health costs to be doubled compared 
without ADT. ADT itself, on the other hand, 
causes bone loss.7 This process can be termed as 
a cancer treatment-induced bone loss (CTIBL).8
From another study, osteopenia was 
found in 27% of normal men and 37% in the 
prostate cancer patients before ADT.9 After 
treatment with ADT, whether it be orchiectomy, 
GonadotropinRealising Hormone (GnRH) with 
or without antiandrogen was causing the rapid 
decline of Bone Mineral Density (BMD) of 
approximately 4% -13% yearly.9,10
The purpose of this paper is to review the 
drugs used to prevent or reduce bone loss from 
prostate cancer metastases and ADT induced 
bone loss.
PHYSIOLOGY AND PATHOPHYSIOLOGY OF 
BONE METASTASES
BMD in middle  l i fe  wil l  decrease 
approximately 0.5-1% per year.10 Risk factors 
for osteoporosis are: hypogonadism, family 
history of osteoporosis, vitamin D deficiency, 
low calcium diet, smoking, excessive alcohol 
and long-term steroid use.11,12
Normal bone remodeling occurs continuously 
regarding the shape and bone repair, which is 
influenced by osteclast and osteoblast.5 Osteoclast 
and osteoblasts communicate via local paracrine 
factors are: Receptor Activator of Nuclear factor 
κB (RANK) and progenitorcell. RANK receptor 
(RANK ligand/RANKL) produced by osteoblasts 
and progenitor cell has a central role in the 
communication process. RANKL and RANK 
bonding induces preosteoclast maturation to 
beosteoclast, which end result of bone resorption 
and release growth factors such as Transforming 
Growth Factor β1 (TGFβ1).
Fibroblasts Growth Factor (FGF), Platelet 
Degradation Growth Factor (PDGF) and Insulin-
like Growth Factor (IGF) stimulate the formation 
osteoblast.8,13 In order for bone formation and 
resorption remain in the balance of osteoblasts 
and stromal cells also produce osteoprotegerin 
(OPG ) which serves as a diversion against the 
RANKL receptor, so the bond does not occur 
RANKL to RANK and induction of osteoclast 
for apoptosis (Figure 1).8
Figure 1. Normal bone cycle, adapted from Miller K7
Estrogen and androgen help to maintain bone 
balance. Estrogen plays a role in bone remodeling 
by inhibiting osteoclast. Androgens reduce bone 
resorption through aromatization of testosterone 
to estrogen. ADT disrupts the hormonal balance 
which bone need.9
Cancer cells metastasize through the blood or 
lymph will stick to the endothelial-specific bone 
marrow and migrate through the gaps between 
cells within 24 hours. Cytokines are found in 
the bone matrix is chemoattractant for prostate 
cancer cells.6 Factors such as bone morphogenic 
Bone Protein-4 (BMP-4) increases tumor cell 
adhesion to bone marrow endothelium. Adhesion 
and extravasation of cancer cells may also be 
facilitated by Protease-Activated Receptor 1 
(PAR1). With the activation of PAR1, cancer cells 
will secrete Matrix Metalloproteinase (MMP). 
MMP causes basement membrane damage and 
facilitates the expansion of bone tissue invasion.6
When the process of osteolysis progresses, 
growth factors in the matrix such as TGFβ, IGF2 
is released, and causes activated osteoblasts in the 
area. Prostate cancer cells secrete BMPs, Prostate 
Specific Antigen (PSA), Parathyroid-related 
hormone (PTHrP) and the protease urokinase 
which have mitogenic effect on osteoblast 
(Figure 2).6
PSA involved in the case of predominantly 
osteoblastic. In addition, PSA will hydrolyze 
IGF-binding proteins that allow IGF-1 to 
stimulate osteoblast proliferation.6
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and osteoporosis less than -2.5.9
Changes in bone density can also be measured 
by markers of bone metabolism. The process of 
formation and bone resorption can be detected 
from serum or urine. These markers can also be 
used to predict the occurrence of SRE, monitoring 
therapeutic efficacy and prognosis.
The marker can see a new bone formation 
such as alkaline phosphatase, osteocalcin and 
amino-terminal procollagen propeptides of 
type 1 collagen (PINP)16 or see the excess 
bone resorptionsuch as: N-telopeptide of type 
1 collagen (NTX)12, cross-linked N-terminal 
telopeptides of type 1 collagen (CTx), Carboxy-
terminal pyridinoline cross-linked telopeptide of 
type 1 collagen (1CTP)17 and RANK.
The National Osteoporosis Foundation 
(NOF) recommends fracture risk assessment with 
the onlineWHO/FRAX® tool (http://www.shef.
ac.uk/FRAX/).18
TREATMENT OF BONE LOSS
Calcium supplement of 1200-1500 mg/day 
in divided doses and vitamin D 400-800 IU/day 
prevents osteoporosis.12,19
Estrogen administration can increase 
bone density and reduce the risk of fractures. 
Oral administration increases the risk for 
thromboembolism; intravenous administration 
is recommended. Another option is to use an 
estradiol patch, obtained from the study will be 
an increase of 3.6% bone density in the spine and 
2.1% at the femoral neck. Side effects of estrogen 
are:gynecodinia 71% and gynecomastia 58%.12
Selective Estrogen Receptor Modulators 
(SERMs)such as Raloxifene and Toremifene also 
protect bone resorption by binding to the estrogen 
receptor on osteoclast and osteoblast.19 This drug 
will increase bone density of about 1%.
Figure 2. Vicious cycle of tumor growth; adapted from Saad F6
ADT INDUCED BONE LOSS
ADT causes testosterone deficiency 
secondary to impaired balance due to normal 
bone formation and resorption resulting in 
increased bone resorption.9,10
Bone loss of a lumbar spine about 4.6%, 
femoral neck 3.9%, hip 9.6%, radius 4.5% in the 
provision of a first year of ADT.6,9 The relative 
risk of fracture associated with an increased dose 
and duration of ADT administration.12 In general, 
the relative risk due to administration of GnRH 
agonist 1.21, pelvic bone fractures1.76 and spinal 
1.18 compared without ADTs.14
Morote et al. study showed that the increase 
in the occurrence of bone loss occurs mainly in 
the first year of ADT administration. Therefore, 
repeated BMD measurement should be done by 
the end of first-year.10,11
BONE DENSITY MEASUREMENT
The modality that can be used to measure 
bone density is dual X-ray absorptiometry (DXA = 
densitometry) and quantitative CT-scan. However, 
the most often used is DXA.9,15 DXA was chosen 
because it can be done quickly and the X-ray dose 
that is lower than conventional X-rays.12
WHO classification considered normal BMD 
if T score of -1 or more, osteopenia -1 to - 2.5 
Risk factors
for fracture:
- ADT
- Prior fracture
Assess BMD:
DXA
T-score -2.5
(osteoporosis)
<
T-score -1.0 to -2.5
(osteoporosis)
T-score -2.5
(osteoporosis)
>
Ensure
adequate
calcium
and
vitamin D
intake
Treatment of
osteoporosis
to prevent
further fracture:
Biphosphonates
Repeat BMD after
6 to 12 months
Repeat BMD
after 2 years
Figure 3. Clinical algorithm for assesment and treatment of ADT associated bone loss9
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The use of nonsteroidal antiandrogen 
bicalutamide 150 mg per day as a single-agent 
increase BMD 2.5%, it is inversely proportional 
to the use of Luteinizing Hormone-Releasing 
Hormone (LHRH) was -5.4%.20 Bicalutamide 
is a competitive inhibitor, inhibit binding of 
dihydrotestosterone to androgen receptor.12
Bisphosphonates is one of the most widely 
used today in the treatment of osteoporosis. 
Bisphosphonates inhibits bone resorption 
mediated osteolaclast, so will prevent bone loss 
and high bone turnover. Bisphosphonates effect 
is influenced by carbon chain R1, which having 
a high ability to bind calcium. Carbon chains 
have been potential of antiresoptive.13 R2 chain 
modification by the addition of nitrogen would 
provide a stronger effect as in the zoledronic acid. 
Zoledronic acid is more potent than clodronate 
100x and etidronate1000x.13
Zoledronic acid will improve the effect of 
tumor cell growth inhibition and cell's apoptosis 
with through caspase pathway.21 It also has 
the effect of reducing the pain caused by bone 
metastasis.
Bisphosphonates per-oral is influenced 
by food and coffee, and therefore, better 
administered intravenously. Side effects of 
bisphosphonates such as: flu-like symptoms, 
acute renal failure (when given rapidly IV) and 
fracture of the jaw. Fracture of the jaw due to 
bisphosphonate administration predisposesby 
the presence of dental problems, steroids use 
and trauma.8,9
Denosumab is a human monoclonal antibody 
(IgG2) developed to specifically target RANK 
Ligand; this is a new option in cases of bone 
metastases.22,23 It mimics the effect of endogenous 
OPG, so denosumab will prevent the bond 
between RANKL and its receptor (Figure 4), 
resulting in a decrease in osteoclast activity and 
bone turnover.22-25
Denosumab use was associated with 
increasedbone mineral density at multiple 
skeletal sitesin women receiving aromatase-
inhibitor therapyfor breast cancer.
Research shows that the denosumab better 
than zoledronic acid in preventing the occurrence 
of SRE.26The adverse events of denosumab were 
comparable to bisphosphonate.22
CONCLUSION
Skeletal complications are a major cause of 
morbidity formen with metastatic prostate cancer. 
Zoledronic acidand denosumab decrease the risk 
of skeletal complications in men with androgen-
independent prostate cancer and bone metastases.
The reduction in risk of skeletal complications 
must be weighed against potential treatment-
related adverse effects.
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